Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pelthos Therapeutics (PTHS) and Viatris (VTRS)

Tipranks - Tipranks - Sat Mar 21, 8:22AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pelthos Therapeutics (PTHS) and Viatris (VTRS).

Claim 70% Off TipRanks Premium

Pelthos Therapeutics (PTHS)

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Pelthos Therapeutics, with a price target of $55.00. The company’s shares closed last Thursday at $22.97.

According to TipRanks.com, Aschoff ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -20.7% and a 29.1% success rate. Aschoff covers the Healthcare sector, focusing on stocks such as Revelation Biosciences, Cellectar Biosciences, and Aptevo Therapeutics. ;'>

Pelthos Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $58.33, a 133.8% upside from current levels. In a report issued on March 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Viatris (VTRS)

In a report released today, Salveen Richter from Goldman Sachs maintained a Hold rating on Viatris, with a price target of $14.00. The company’s shares closed last Thursday at $13.50, close to its 52-week high of $13.55.

According to TipRanks.com, Richter is a 5-star analyst with an average return of 10.8% and a 46.8% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, 4D Molecular Therapeutics, and Vertex Pharmaceuticals. ;'>

Viatris has an analyst consensus of Moderate Buy, with a price target consensus of $14.67, a 6.7% upside from current levels. In a report released today, Piper Sandler also reiterated a Hold rating on the stock with a $12.00 price target.

Read More on PTHS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).